Decisions regarding the initiation of cancer therapy have become increasingly complex in the era of coronavirus disease 2019 (COVID-19). Health care professionals and patients must balance the benefits and risks of immediate treatment for cancer with the potential subsequent increases in the risk of COVID-19 and its associated complications, including death. Unlike approaches that triage cancer treatment using a tiered approach, Hartman et al1 have developed a web-based comprehensive model (OncCOVID) to estimate the risk of delaying the initiation of cancer treatment for an individual patient with cancer. This model estimates risk for patients with cancer of varying types and stages, and it incorporates other known risk factors for COVID-19, such as comorbidities, patient age, local COVID-19 prevalence, and reproduction number (which reflects the mean number of new patients with infections by each case in a region). The model is based on the use of epidemiologic data regarding treatment delays and outcomes from patients with cancer to estimate the risk of delayed treatment for a specific patient based on individual risk profile. The model has been developed into a useful application with a simple and intuitive interface. The web-based interface provides an accessible platform that can be used on a smartphone. Many of the necessary inputs for the model have default values that can be modified (for quantities such as relative risk [RR] of infection and other parameters that may vary across cancer care practice or treatment setting), but the user is required to input data on patient-level characteristics.
Sign in to take quiz and track your certificates
JN Learning™ is the home for CME and MOC from the JAMA Network. Search by specialty or US state and earn AMA PRA Category 1 Credit(s)™ from articles, audio, Clinical Challenges and more. Learn more about CME/MOC
CME Disclosure Statement: Unless noted, all individuals in control of content reported no relevant financial relationships. If applicable, all relevant financial relationships have been mitigated.
Corresponding Author: Elizabeth Garrett-Mayer, PhD, Center for Research and Analytics, American Society of Clinical Oncology, 2318 Mill Rd, Ste 800, Alexandria, VA 22314 (email@example.com).
Published Online: October 29, 2020. doi:10.1001/jamaoncol.2020.4886
Conflict of Interest Disclosures: Dr Rini reported receiving grants and personal fees from AVEO Pharmaceuticals, Bristol Myers Squibb, Genentech, Merck, and Pfizer and personal fees from Alkermes, Aravive, AstraZeneca, and GlaxoSmithKline outside the submitted work. No other disclosures were reported.
You currently have no searches saved.
You currently have no courses saved.